Under construction – not a live service
Sign in
Taking people in ItalyPhase 1

Testing mosunetuzumab, alone or with venetoclax, in chronic lymphocytic leukemia that returned

Tests mosunetuzumab, alone or with venetoclax, in adults whose leukemia returned or stopped responding.

Key facts

Who runs it
F. Hoffmann-La Roche AG
Where
Brescia, Milan, and Perugia, ItalySee the 4 sitesAlso in 4 other countries, 9 sites
Registry title
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Status
Recruiting
Phase
Phase 1
People taking part
54 people, planned
Started
17 Jun 2022
Expected to end
30 Oct 2027
Type of study
Interventional
Record updated
3 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose chronic lymphocytic leukemia (CLL) has come back or has not responded to earlier treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Chronic lymphocytic leukemia (CLL) that has come back (relapsed) or has not responded to treatment (refractory)

Where in Italy

Also in 4 other countries, 9 sites

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaBrescia, ItalyTaking people
  • ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyTaking people
  • Ospedale San Raffaele S.r.l.Milan, ItalyTaking people
  • Hospital Santa Maria Della MisericordiaPerugia, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Testing mosunetuzumab, alone or with venetoclax, in chronic lymphocytic leukemia that returnedGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
3 August 2026